

Airway remodelling in children with cystic fibrosis

Tom N Hilliard^{1,2}

Nicolas Regamey^{1,2}

Janis K Shute³

Andrew G Nicholson⁴

Eric WFW Alton²

Andrew Bush¹

Jane C Davies^{1,2}

¹ Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London

² Department of Gene Therapy, National Heart and Lung Institute, Imperial College, London

³ Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, Portsmouth

⁴ Department of Histopathology, Royal Brompton Hospital, London

Correspondence and requests for reprints to:

Dr Tom Hilliard, Department of Paediatric Respiratory Medicine, Royal Hospital for Children, Bristol, BS2 8BJ, UK

Tel: 0117 342 8693

Fax: 0117 342 8494

Email: tom.hilliard@ubht.nhs.uk

Key words: child; cystic fibrosis; extracellular matrix; inflammation; pathology.

Word count: 3591

Abstract

Background: The relationship between airway structural changes and inflammation is unclear in early cystic fibrosis (CF) lung disease.

Objective: To determine changes of airway remodelling in children with CF, compared with appropriate disease and healthy controls.

Methods: Bronchoalveolar lavage and endobronchial biopsy were performed in a cross-sectional study of 43 children with CF (aged 0.3 to 16.8 years), 7 children with primary ciliary dyskinesia (PCD), 26 children with chronic respiratory symptoms (CRS) investigated for recurrent infection and/or cough, and 7 control children with no lower airway symptoms. Inflammatory cells, cytokines, proteases and matrix constituents were measured in bronchoalveolar lavage fluid (BALF). Reticular basement membrane (RBM) thickness was measured on biopsies using light microscopy.

Results: Increased concentrations of elastin, glycosaminoglycans and collagen were found in CF BALF compared to the CRS group and controls, each correlating positively with age, neutrophil count and proteases (elastase activity and MMP-9 concentration). There were significant negative correlations between certain of these and pulmonary function (FEV₁) in the CF group (elastin $r=-0.45$, $p<0.05$ and MMP-9:TIMP-1 ratio $r=-0.47$, $p<0.05$). Median RBM thickness was greater in the CF group (5.9 μm) than controls (4.0 μm , $p<0.01$), and correlated positively with levels of transforming growth factor- β_1 (TGF- β_1 $r=0.53$, $p=0.01$), although not with other inflammatory markers or pulmonary function.

Conclusions: This study provides evidence for two forms of airway remodelling in children with CF: firstly, matrix breakdown, related to inflammation, proteolysis and impaired pulmonary function, and secondly, RBM thickening, related to TGF- β_1 concentration but independent of other markers of inflammation.

Abbreviations

BALF, bronchoalveolar lavage fluid

CF, cystic fibrosis

CFTR, cystic fibrosis transmembrane regulator

CRS, chronic respiratory symptoms

FEV₁, forced expiratory volume in the first second

GA, general anaesthesia

GAG, glycosaminoglycans

HRCT, high resolution computed tomography

IL, interleukin

MMP, matrix metalloproteinase

NE, neutrophil elastase

PCD, primary ciliary dyskinesia

PFT, pulmonary function tests

RBM, reticular basement membrane

TGF- β ₁, transforming growth factor- β ₁

TIMP-1, tissue inhibitor of metalloproteinases-1

Newborns with cystic fibrosis (CF) have structurally normal airways, but at the time of death or lung transplantation, there is severe airway destruction and extensive bronchiectasis.¹ It has been assumed that these structural airway wall changes have occurred secondary to infection and inflammation. In asthma, airway remodelling has been thought to follow chronic airway inflammation², but recent evidence has challenged this assumption, suggesting instead that remodelling may be an independent, parallel process.³ Whether remodelling in CF is secondary to infection and inflammation, or a separate process, is of potential importance; if the former, then treatment of infection and inflammation could preserve airway function. But if remodelling is a separate process, relating to some aspect of CFTR dysfunction, new therapeutic approaches to preserve airway function may be required.

Neutrophilic inflammation within the airway lumen in CF is central to the pathophysiology of the disease, and can occur within the first few months of life.⁴ However, most previous work on airway wall pathology has come from explanted lungs, or at autopsy. Little is known about the nature of histological changes in the airway wall in children with relatively mild disease or early stage disease, and how these changes may relate to inflammation within the airway lumen.

Investigation of airway remodelling in CF to date has attempted to establish alterations in airway components, cytokines and proteases that appear important in asthma. Although there may be airway smooth muscle hyperplasia in adult CF biopsies compared to controls,⁵ it is unclear whether there is thickening of the reticular basement membrane (RBM) and whether any of these changes are seen in the paediatric age group.^{6 7} However, biopsy immunoreactivity against transforming growth factor- β_1 (TGF- β_1), a cytokine known to be pro-fibrotic *in vitro*,⁸ appeared to be associated with a better clinical picture.⁷ Increased levels of matrix metalloproteinase-9 (MMP-9) have been found in sputum and bronchoalveolar lavage fluid (BALF) from children with CF.^{9 10} Furthermore, increased breakdown products

of airway matrix components have been found in urine¹¹ and sputum¹² of CF patients, but with no clear relationship with pulmonary function.

We have previously shown that infants with CF have impaired lung function at diagnosis, irrespective of current or previous respiratory problems,¹³ and that there is no catch-up in lung function in the preschool years, despite intensive treatment in specialist centres.¹⁴ We therefore hypothesised that structural airway wall changes are present early in the course of CF, and that, as with atopic asthma, they may not be directly related to infection or inflammation. To this end, we compared endobronchial biopsies and BALF from children with CF to those from disease and healthy control groups. We studied matrix degradation and thickening of the RBM and looked for relationships with markers of airway inflammation and infection.

METHODS

Subjects

Subjects were prospectively recruited from the following 4 groups of children:

(i) CF, diagnosed using standard criteria,¹⁵ who were undergoing bronchoscopy for a clinical indication, or having a general anaesthetic for another clinically indicated procedure; (ii) primary ciliary dyskinesia (PCD),¹⁶ who were undergoing bronchoscopy during a pulmonary exacerbation; (iii) chronic respiratory symptoms (CRS), who were being electively investigated for a history of recurrent infections and/or persistent or recurrent cough; (iv) controls, who had no history of lower airway problems (3 had recurrent croup, 1 had previous self-reported haemoptysis, 1 had stridor, and 2 were undergoing cardiac catheterisation where informed consent was given to perform bronchoscopy for research reasons).

Prior to bronchoscopy, spirometry was performed according to American Thoracic Society guidelines¹⁷ with a Vitalograph 2120 spirometer (Vitalograph, Ennis, Ireland) and reference data ERS/Polgar. The study was approved by the Research Ethics Committees of the Royal Brompton and Chelsea & Westminster Hospitals. Fully informed consent was obtained from parents, and age-appropriate assent from the children.

Bronchoscopy

All bronchoscopies were performed under general anaesthesia (GA). Bronchoalveolar lavage was performed using three aliquots of 1 ml/kg of room temperature 0.9% saline, instilled separately into the right middle lobe, unless otherwise indicated, and the return mixed. Up to three endobronchial biopsies were taken under direct vision from sub-carinae of segmental bronchi in the right lower lobe with FB-56D-1 rat tooth or FB-231D oval fenestrated jaw forceps (Olympus, Tokyo, Japan), depending on the size of the bronchoscope, and placed in 10% formalin in saline.

BALF Analysis

BALF was kept on ice and processed within 2 hours. Quantitative microbiology was performed on chocolate, Colombia Blood Agar, Saboraud, Mannitol Salt Agar, Maconkey, *Pseudomonas* isolation and *Burkholderia cepacia* media. Viruses (RSV, parainfluenza 1, 2 and 3, influenza A and B, adenovirus, and cytomegalovirus) were detected using direct immunofluorescence and/or rapid viral tissue culture. Cell counts were performed using a dual chamber Neubauer Haemocytometer (Assistant, Sondheim, Germany). Remaining BALF was centrifuged at 2000g for 10 minutes, the supernatant removed and stored in aliquots at -80°C for later analysis. The cell pellet was then washed, 0.1% dithiothreitol added as a mucolytic, washed again, and then re-suspended for a cytospin preparation. Cell differential was assessed using May-Grunwald-Giemsa staining and counting at least 300 identifiable cells.

IL-8, IL-10, IL-13 and total TGF- β_1 were measured using commercial ELISA kits (DuoSet, R&D Systems Inc, Minneapolis, MN, USA). IL-10 was measured with and without protease inhibition (1% 0.5M EDTA (Gibco), 1% Protease inhibitor P8340 (Sigma-Aldrich, St Louis, MO, USA), 1% BSA (Sigma-Aldrich)). IL-13 and TGF- β_1 were measured with protease inhibition. Neutrophil elastase (NE) activity was measured using an assay based on NE cleavage of nitroanilide from N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide (Sigma-Aldrich). MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured using Biotrak ELISA kits (Amersham Biosciences, Buckinghamshire, UK). Elastin, glycosaminoglycans, and collagen were measured using dye binding assay kits (Biocolor, Newtonabbey, Northern Ireland).

Biopsy Analysis

Formalin-fixed paraffin-embedded sections (3-5 μm thickness) were stained with haematoxylin and eosin. One section from each patient was selected which showed identifiable epithelium and submucosa with at least 800 μm of basement membrane. RBM thickness was measured on coded sections using light microscopy and computer-aided image analysis (NIH Image 1.55; National Institutes of Health, Bethesda, MD), by taking the geometric mean of 40 measurements at 20 μm intervals, as previously described.^{18 19}

Statistical analysis

Nonparametric tests were applied to test for intergroup differences. Associations were looked for by Spearman rank correlation. The chi-squared test was used to test for differences in the distribution of categorical variables. A p value of less than 0.05 was deemed statistically significant, except for multiple comparisons (CF *vs* each of 3 different groups), when 0.017 was used. SPSS v11.5 (SPSS Inc, Chicago, IL, USA) was used for statistical analysis.

RESULTS

Subjects

Demographics of the 83 children who underwent bronchoscopy are summarised in table 1. In the CF group, bronchoscopy was performed during a pulmonary exacerbation in 31 children (72%, 26 of whom were on intravenous (IV) antibiotic therapy) and during a period of clinical stability in 12 (28%). The primary reason for bronchoscopy in the CF group is broken down by age in table 2, with the indications detailed separately for those under and over 6 years. It is our routine clinical practice to bronchoscope following diagnosis, and this was the indication in 9 of the 11 very young children (<2 years); bronchoscopy was performed during a pulmonary exacerbation in the other 2 children, one of whom was having line insertion under general anaesthesia. Of the 43 children with CF, 40 had genotypes available; 27 were $\Delta F508$ homozygotes (68%), 10 were compound $\Delta F508$ heterozygotes, 2 were G551D/-, and 1 was N1303K/N1303K.

Bronchoscopy

The right middle lobe was used for bronchoalveolar lavage in 71 cases (86%). Endobronchial biopsies were taken during 78 bronchoscopies (94%); between 1 (4 patients) and 3 (70 patients) biopsies were performed. All patients in the control group, including the one with suspected haemoptysis, had a normal lower airway on bronchoscopy and subsequent negative BALF cultures. No patient had any overt complication from endobronchial biopsy.

Table 1 Demographics, cell counts, cytokines, proteases and matrix constituents in BALF in each patient group

	CF	PCD	CRS	Controls
Number	43	7	26	7
Age, years	6.2 (0.3-16.8)	9.2 (5.7-14.8)	4.8 (0.9-15.2)	5.8 (0.3-16.3)
Sex, male (%)	14 (33%)	2 (29%)	13 (50%)	4 (57%)
FEV ₁ % predicted †	60 (29-91)	66 (46-89)	89 (75-94)***	87 (82-118)
FVC % predicted †	81 (32-114)	82 (48-102)	103 (82-118)**	97 (86-108)
Total cells (x10 ⁶ /ml)	1.7 (0.21-28.5)	0.7 (0.16-14.80)	0.3 (0.12-20.43)***	0.3 (0.12-0.46)***
Neutrophils (x10 ⁶ /ml)	0.7 (0.02-23.97)	0.3 (0.05-13.76)	0.0 (0.00-17.91)***	0.0 (0.00-0.01)***
Eosinophils (x10 ⁶ /ml)	0.0 (0.00-0.22)	0.0 (0.00-0.09)	0.0 (0.00-0.10)**	0.0 (0.00-0.00)**
IL-8 (pg/ml)	1340 (31-1760)	1272 (714-1374)	703 (31-1560)***	64 (31-221)***
IL-10 ‡ (pg/ml)	15 (15-74)	44 (15-68)	32 (15-108)***	29 (24-51)*
IL-13 ‡ (pg/ml)	23 (23-95)	23 (23-23)	27 (23-73)**	26 (23-82)**
TGF-β ₁ ‡ (pg/ml)	78 (2-265)	131 (22-331)	17 (2-211)***	2 (2-8)***
Neutrophil elastase (mu/ml)	201 (100-5000)	180 (100-3502)	100 (100-1297)***	100 (100-100)**
MMP-9 (ng/ml)	185 (2-2454)	221 (59-3334)	46 (1-3188)***	4 (1-6)***
TIMP-1 (ng/ml)	105 (7-2629)	150 (26-770)	113 (11-994)	39 (13-214)
Molar ratio MMP9:TIMP-1	0.4 (0.01-28.16)	0.4 (0.02-35.05)	0.0 (0.01-26.51)***	0.0 (0.00-0.08)***
Glycosaminoglycans (µg/ml)	59 (2-120)	61 (2-89)	2 (2-48)***	2 (2-7)***
Elastin (µg/ml)	424 (125-2000)	417 (125-2000)	149 (125-1698)**	54 (125-204)**
Collagen (µg/ml)	25 (5-412)	195 (5-500)	5 (5-68)***	5 (5-5)***

Median (range) for each parameter shown. CF vs PCD, CRS or controls: * p<0.017, ** p<0.01, *** p<0.001.

† number of children performing spirometry: CF 23; PCD 7, CRS 7, controls 2.

‡ measured with protease inhibitors.

Table 2 Reason for bronchoscopy in the CF group

	< 6 years	≥ 6 years	Total	%
New diagnosis and well	10	-	10	23
New diagnosis with exacerbation	1	1	2	5
Exacerbation before IV antibiotics	2	5	7	16
Exacerbation not responding to IV antibiotics	4	8	12	28
Line insertion during exacerbation	3	5	8	19
Collapsed lobe during exacerbation	1	-	1	2
Gastrostomy change during exacerbation	-	1	1	2
Port insertion while well	-	1	1	2
Port removal while well	-	1	1	2
Total	21	22	43	100

BALF analysis

Pathogenic bacteria were found in 13 BALF samples from the CF group (30%), including in 8 of the 26 children (31%) on intravenous antibiotic therapy, in 4 (57%) of the PCD and 12 (46%) of the CRS groups. *Pseudomonas aeruginosa* was detected in 7 of the CF group (16%). Parainfluenza 3 was detected in BALF from one of the CF group.

Cell counts, cytokine and protease concentrations in BALF are shown in table 1. Total cell, neutrophil, IL-8 and TGF- β_1 concentration were significantly higher in the CF group compared with the CRS and control groups; concentrations were similar in the PCD group. With protease inhibition, IL-10 was detected in 29% of CF samples, compared with 83% of PCD, 79% of CRS and 100% of control samples ($\chi^2=21.8$, $p<0.001$). Without protease inhibition, IL-10 was detected in 9% of CF samples ($p<0.05$).

NE activity, MMP-9 concentration and molar ratios of MMP-9 to its inhibitor TIMP-1 were significantly higher in the CF group compared to the CRS and control groups, but similar to the PCD group, as shown in table 1. TIMP-1 concentrations were similar between groups. In the CF group, NE activity correlated negatively with FEV₁ ($r=-0.44$, $p<0.05$). MMP-9 concentration did not correlate with any spirometric index, but the molar ratio of MMP-9: TIMP-1 correlated negatively with FEV₁ in the CF group ($r=-0.47$, $p<0.05$, figure 1). MMP-9 concentration correlated with neutrophil concentration in the CF group ($r=0.71$, $p<0.001$).

Matrix constituent concentrations are shown in table 1, and individual concentrations of glycosaminoglycans shown in figure 2. Glycosaminoglycan, elastin and collagen concentrations were significantly higher in the CF group compared with the CRS and control groups, but were similar to the PCD group. Within the CF group, correlations of matrix constituent concentrations and age, neutrophil and MMP-9 concentration, NE activity and FEV₁ are shown in table 3. In particular, glycosaminoglycans correlated positively with

neutrophil concentration ($r=0.85$, $p<0.001$, figure 3), and elastin correlated negatively with FEV₁ ($r=-0.45$, $p<0.05$, figure 4). In CF cases under the age of 6 years, 85% had glycosaminoglycan concentrations above the upper limit of the control group, as did 53% for elastin and 62% for collagen.

No marker of inflammation or remodelling correlated with concentration of pathological bacterial concentration and there was no difference in these parameters between cases with or without *Pseudomonas aeruginosa* identified in BAL, or between $\Delta F508$ homozygotes and other genotypes. The only parameters that were significantly different between those CF cases with an exacerbation compared to those who were well or clinically stable were the total cell count (2.3×10^6 vs 1.0×10^6 /ml, $p<0.05$), neutrophil concentration (1.0×10^6 vs 0.4×10^6 /ml, $p<0.05$) and glycosaminoglycan concentration (65 vs 27 $\mu\text{g}/\text{ml}$, $p<0.05$).

Table 3 Correlations between matrix constituent concentrations in BALF and age, neutrophil and MMP-9 concentration, NE activity and FEV₁ in the cystic fibrosis group

	Age, years	Neutrophils, cells/ml	NE activity, mu/ml	MMP-9, ng/ml	FEV₁, % predicted
Glycosaminoglycans, µg/ml	r=0.62, p<0.001 (0.40-0.80)	r=0.85, p<0.001 (0.73-0.92)	r=0.77, p<0.001 (0.59-0.87)	r=0.77, p<0.001 (0.59-0.87)	r=-0.32, ns (-0.60-0.25)
Elastin, µg/ml	r=0.40, p<0.05 (0.03-0.63)	r=0.82, p<0.001 (0.63-0.90)	r=0.72, p<0.001 (0.49-0.85)	r=0.59, p<0.001 (0.29-0.76)	r=-0.45, p<0.05 (-0.74--0.01)
Collagen, µg/ml	r=0.45, p<0.01 (0.13-0.71)	r=0.75, p<0.001 (0.52-0.88)	r=0.75, p<0.001 (0.57-0.89)	r=0.74, p<0.001 (0.46-0.85)	r=-0.18, ns (-0.55-0.35)

Spearman rank correlations shown, with 95% confidence intervals; ns = not significant.

RBM thickness

Of the 78 patients in whom endobronchial biopsies were taken, 50 (64%) had at least one biopsy that was of sufficient quality for RBM thickness to be measured. Biopsy success rate was 59% in CF cases and 69% in non-CF cases; there was a lower success rate with small forceps (1.2 mm biopsy channel) compared with large forceps (2 mm biopsy channel) (33% vs 90%; $\chi^2=14.54$, $p<0.001$).

RBM thickness in each patient group is shown in figure 5. Median RBM was significantly thicker in the CF group (5.9 μm) compared to controls (4.0 μm , $p<0.01$) but similar to the CRS (4.6 μm) and PCD groups (4.6 μm). 18 of the 24 (75%) biopsies in the CF group had a RBM thickness greater than the upper limit of the control group (4.5 μm). There was no difference in RBM thickness between the 5 CF patients who were stable and the 19 with an exacerbation (5.8 vs 6.1 μm). In the CF group, there was no relationship between RBM thickness and age; a RBM greater than 4.5 μm was present in 5 children with CF under the age of 6 years (including 2 infants). RBM thickness correlated with total TGF- β_1 concentration ($r=0.53$, $p=0.01$, figure 6) but not with PFTs, dose of inhaled corticosteroids, BALF cell count, pathological bacterial load, or other cytokine or protease concentration.

DISCUSSION

This is the first study to investigate airway remodelling using both BALF and endobronchial biopsies in a large group of children with CF. We found evidence for two forms of airway remodelling in children with CF; firstly, matrix breakdown, as demonstrated by increased levels of matrix components in BALF, related to increased neutrophils and proteases and decreased pulmonary function; and secondly, RBM thickening which was related to TGF- β_1 concentration, but not to other inflammatory markers or lung function.

This study confirms higher levels of NE and MMP-9 in BALF in CF.⁹ However, contrary to previous work⁹, the concentration of TIMP-1, the inhibitor of MMP-9, was not increased in our patients. In asthma, the molar ratio of MMP-9 to TIMP-1 has been found to be lower than in controls and to correlate positively with FEV₁,²⁰ with an excess of TIMP-1 implicated in increased collagen deposition.²¹ In the present study the molar ratio of MMP-9 to TIMP-1 was higher in the CF group than controls and correlated negatively with FEV₁. In asthma, higher levels of TIMP-1 to MMP-9 may protect against airway wall destruction. We speculate that the opposite may be true in CF, where an imbalance of MMP-9 over its inhibitor may result in destruction of the airway wall.

The extracellular matrix is a complex network within the airway wall consisting of fibrous (collagen and elastin) and adhesive (fibronectin and laminin) proteins, embedded in a hydrated polysaccharide gel containing glycosaminoglycans, which provide rigidity to the airway wall.² Previous studies have found increased breakdown products of elastin^{11 22} and collagen¹¹ in the urine of CF patients, but no clear relationship between these and lung function. Although alteration to the extracellular matrix is a recognised finding in endobronchial biopsies in asthmatics,²³ this is the first study, to our knowledge, to measure matrix components in BALF. We have demonstrated increased concentrations of elastin, GAG and collagen in BALF in the CF group compared to the CRS and control groups,

correlating with neutrophil concentration, neutrophil elastase activity and MMP-9 concentration. This is compatible with the hypothesis that these components are being broken down by proteases and being released into the airway lumen. Elastin concentration also correlated negatively with FEV₁, and GAG concentration was significantly higher in those CF cases with an exacerbation. In addition, concentrations of matrix components were increased above control values even in very young children with CF, suggesting that this process begins early. The extracellular matrix appears to be involved in airway development and repair,²⁴ and may play a role in cell chemoattraction.²⁵ It is plausible that the presence of matrix components in the airway lumen may themselves act to further heighten inflammation. This could be usefully tested in an *in vitro* model of neutrophil migration.

Median RBM thickness in the CF group was greater than the control group, but was similar to that in the PCD and CRS groups. The median thickness (6.1 μm) was less than that reported in children with difficult asthma (8.2 μm),¹⁹ although similar to that reported for children with mild to moderate asthma.²⁶ RBM thickness in the control cases was similar to that previously reported.²⁶ Although RBM thickness has not been previously measured in CF, biopsy studies have examined the sub-epithelial area, reporting a fibrotic layer beneath the true basement membrane⁶ and showing a thickened RBM in a figure in one publication.⁷ RBM thickening would therefore appear to be present in CF, and occur early, contrary to the lack of RBM thickening in infants with wheeze less than 2 years of age.²⁷ There appeared to be a clustering of RBM thickness around 3 to 4 μm in the CRS group, suggesting that the cases with thicker RBM may be outliers and reflecting the mixed pattern of respiratory disease within this group. RBM thickening would therefore not appear to be a specific feature of asthma, and it has also been reported in other disease states such as atopy.²⁶

In the present study, RBM thickness correlated with TGF- β ₁ concentration in BALF. Although RBM thickness correlated with TGF- β ₁ reactivity in adult asthmatic biopsies,²⁸ this

has not been previously found with TGF- β_1 levels in BALF.²⁹ The correlation with RBM thickness fits well with the known effect of TGF- β_1 as a potent *in vitro* stimulator of collagen production,⁸ which likely forms part of the RBM. An association has also been found between TGF- β_1 polymorphisms and disease severity in CF.³⁰ The numbers in our study were too small to look for an effect of TGF- β_1 polymorphisms. However, TGF- β_1 immunoreactivity in biopsies from patients with CF has previously been associated with a better FEV₁ and fewer exacerbations.⁷ This would suggest some benefit from the presence of TGF- β_1 , which also has anti-inflammatory properties.⁸ The functional consequence of RBM thickening is currently unclear, and it is not known if it is detrimental to airway function, or if it may provide some resistance to airway compression. The discrepancy between airway destructive processes and RBM thickening is intriguing, and is suggestive that RBM thickening could conceivably be a protective response, as has been suggested for asthma³¹

There are few data available on the inflammatory profile in the lower airways in PCD, although a recent study of sputum from children with PCD reported a median neutrophil differential of 70%.³² The present study demonstrates a very similar picture to CF, in terms of neutrophil, IL-8 and protease concentrations, despite the generally milder clinical phenotype seen in PCD. There were also similar concentrations of matrix components, demonstrating that matrix breakdown is not specific to CF. The high matrix concentrations in PCD BALF tended to be present in those samples with higher inflammatory markers, so it would appear to be linked with heightened inflammation as was observed for CF. However, all of this small group were studied during an exacerbation, and this may not therefore be representative of PCD patients in general.

We also measured concentrations of IL-10, an anti-inflammatory cytokine, and IL-13, a Th₂ cytokine which appears to be involved in the development of murine asthma models.³³ With the addition of protease inhibitors to thawing BALF, IL-10 was detected in significantly

fewer BALF samples in the CF group compared with the CRS and control groups, contrary to previous studies.³⁴ Without the use of protease inhibition, IL-10 was detected in even fewer CF samples, which indicates that IL-10 is degraded by proteases in BALF. This suggests that protease inhibition is required for its accurate measurement, contrary to that previously reported.³⁵ IL-13 was similar between groups, and therefore we have no evidence that it is present in altered amounts in CF.

Inevitably, this study has a number of limitations. The opportunistic nature of sampling necessitated that the study was cross sectional, and included CF children with a wide range of age and disease severity. In addition, patients with exacerbations were studied at differing time points in their disease process, when their physicians thought that a bronchoscopy was clinically indicated. Thus, we cannot confirm whether the correlations between markers of remodelling and inflammation are causative or merely associations. The CRS group was a mixed group of children with a variety of disease processes. The control group provided a better comparison for children who were unlikely to have lower airway disease, but it was small, reflecting the difficulty of obtaining control tissue of this type in children. Because the CF group was relatively young, with a median age of 6 years, only half of the group were old enough to perform spirometry. This therefore reduces the power of the study to look for correlations with PFTs. Further, endobronchial biopsies were performed at a sub-carina in the right lower lobe, in a 4th to 5th generation airway. CF, however, is a disease process that affects airways throughout the bronchial tree and therefore changes in a relatively large airway may not reflect what is occurring in smaller airways, and which may be demonstrated in BALF. We also have not been able to separate any differential effects of disease between airway or parenchymal components; a limitation of BAL sampling is that it will also reflect changes peripherally in the lung parenchyma. We were not able to obtain biopsies on all children; it was difficult to biopsy the airways using small forceps, especially

if there was a lot of mucus in the airway. We would have liked to examine deeper structures in the airway wall, but for obvious reasons, a full thickness biopsy could not be obtained. Although detailed quantitative microbiology was performed on BALF, we did not widen our analysis to historical BALF or non-invasive cultures, and we accept that this is a weakness in the study. Our study focused on only two aspects of remodelling, namely thickness of the reticular basement membrane and matrix degradation. Further work will examine other features of remodelling, such as quantification of airway smooth muscle and matrix components in the sub-mucosa. Combining invasive investigations with pulmonary function tests appropriate for younger children, such as multiple breath washout, and imaging, particularly HRCT, may be useful. Finally, this was by definition an exploratory observational study and we had no prior data with which to perform power calculations. We have attempted to limit type 1 error by applying lower p value to analyses involving multiple groups, but as we analysed many outcome variables, our positive results must be interpreted with some caution and ideally reproduced in a second cohort.

In conclusion, this study provides evidence for two forms of airway remodelling in children with CF. Matrix breakdown correlates positively with BALF proteases and negatively with pulmonary function. RBM thickening also occurs in CF and is related to TGF- β_1 concentration, but not to other inflammatory markers or lung function. These processes occur early in life in CF, and matrix breakdown in particular may be a therapeutic target to delay deterioration in pulmonary function.

Acknowledgments

The authors thank Neil Madden for help with the quantitative microbiology; Chloe Dunn and Bernie Ortega for their assistance with bronchoscopies; Pat Haslam for help with cytospin analysis; the Department of Pathology, Royal Brompton Hospital for their preparation of biopsy material; Ian Balfour-Lynn and Mark Rosenthal for the inclusion of their patients in the study and for performing bronchoscopy. They also gratefully acknowledge the patients and families that agreed to take part in the study.

Competing interests

None declared.

Funding

This work was supported by a Swiss National Foundation grant 1172/05 and ERS fellowship 64/05 to NR.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Thorax editions and any other BMJPG Ltd products to exploit all subsidiary rights, as set out in our licence (<http://thorax.bmjournals.com/ifora/licence.pdf>).

REFERENCES

- 1 **Gibson RL**, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. *Am J Respir Crit Care Med* 2003;**168**:918-951.
- 2 **Bousquet J**, Jeffery PK, Busse WW, *et al.* Asthma. From bronchoconstriction to airways inflammation and remodeling. *Am J Respir Crit Care Med* 2000;**161**:1720-1745.
- 3 **Jeffery PK**. Remodeling in asthma and chronic obstructive lung disease. *Am J Respir Crit Care Med* 2001;**164**:S28-S38.
- 4 **Khan TZ**, Wagener JS, Bost T, *et al.* Early pulmonary inflammation in infants with cystic fibrosis. *Am J Respir Crit Care Med* 1995;**151**:1075-1082.
- 5 **Hays SR**, Ferrando RE, Carter R, *et al.* Structural changes to airway smooth muscle in cystic fibrosis. *Thorax* 2005;**60**:226-228.
- 6 **Durieu I**, Peyrol S, Gindre D, *et al.* Subepithelial fibrosis and degradation of the bronchial extracellular matrix in cystic fibrosis. *Am J Respir Crit Care Med* 1998;**158**:580-588.
- 7 **Wojnarowski C**, Frischer T, Hofbauer E, *et al.* Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation. *Eur Respir J* 1999;**14**:1136-1144.
- 8 **Bartram U**, Speer CP. The role of transforming growth factor beta in lung development and disease. *Chest* 2004;**125**:754-765.
- 9 **Ratjen F**, Hartog CM, Paul K, *et al.* Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. *Thorax* 2002;**57**:930-934.

- 10 **Sagel SD**, Kapsner RK, Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. *Pediatr Pulmonol* 2005;**39**:224-232.
- 11 **Stone PJ**, Konstan MW, Berger M, *et al*. Elastin and collagen degradation products in urine of patients with cystic fibrosis. *Am J Respir Crit Care Med* 1995;**152**:157-162.
- 12 **Rahmoune H**, Lamblin G, Lafitte JJ, *et al*. Chondroitin sulfate in sputum from patients with cystic fibrosis and chronic bronchitis. *Am J Respir Cell Mol Biol* 1991;**5**:315-320.
- 13 **Ranganathan SC**, Dezateux C, Bush A, *et al*. Airway function in infants newly diagnosed with cystic fibrosis. *Lancet* 2001;**358**:1964-1965.
- 14 **Ranganathan SC**, Stocks J, Dezateux C, *et al*. The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis. *Am J Respir Crit Care Med* 2004;**169**:928-933.
- 15 **Rosenstein BJ**, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. *Journal of Pediatrics* 1998;**132**:589-595.
- 16 **Bush A**, Cole P, Hariri M, *et al*. Primary ciliary dyskinesia: diagnosis and standards of care. *Eur Respir J* 1998;**12**:982-988.
- 17 **Anon**. Standardization of Spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med* 1995;**152**:1107-1136.
- 18 **Sullivan P**, Stephens D, Ansari T, *et al*. Variation in the measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. *Eur Respir J* 1998;**12**:811-815.
- 19 **Payne DN**, Rogers AV, Adelroth E, *et al*. Early thickening of the reticular basement membrane in children with difficult asthma. *Am J Respir Crit Care Med* 2003;**167**:78-82.

- 20 **Vignola AM**, Riccobono L, Mirabella A, *et al.* Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. *Am J Respir Crit Care Med* 1998;**158**:1945-1950.
- 21 **Mautino G**, Capony F, Bousquet J, *et al.* Balance in asthma between matrix metalloproteinases and their inhibitors. *J Allergy Clin Immunol* 1999;**104**:530-533.
- 22 **Bruce MC**, Poncz L, Klinger JD, *et al.* Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. *Am Rev Respir Dis* 1985;**132**:529-535.
- 23 **Huang J**, Olivenstein R, Taha R, *et al.* Enhanced proteoglycan deposition in the airway wall of atopic asthmatics. *Am J Respir Crit Care Med* 1999;**160**:725-729.
- 24 **McGowan SE**. Extracellular matrix and the regulation of lung development and repair. *FASEB J* 1992;**6**:2895-2904.
- 25 **Parameswaran K**, Radford K, Zuo J, *et al.* Extracellular matrix regulates human airway smooth muscle cell migration. *Eur Respir J* 2004;**24**:545-551.
- 26 **Barbato A**, Turato G, Baraldo S, *et al.* Airway inflammation in childhood asthma. *Am J Respir Crit Care Med* 2003;**168**:798-803.
- 27 **Saglani S**, Malmstrom K, Pelkonen AS, *et al.* Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. *Am J Respir Crit Care Med* 2005;**171**:722-727.
- 28 **Vignola AM**, Chanez P, Chiappara G, *et al.* Transforming Growth Factor-beta Expression in Mucosal Biopsies in Asthma and Chronic Bronchitis. *Am J Respir Crit Care Med* 1997;**156**:591-599.
- 29 **Redington AE**, Madden J, Frew AJ, *et al.* Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. *Am J Respir Crit Care Med* 1997;**156**:642-647.

- 30 **Drumm ML**, Konstan MW, Schluchter MD, *et al.* Genetic modifiers of lung disease in cystic fibrosis. *N Engl J Med* 2005;**353**:1443-1453.
- 31 **Milanese M**, Crimi E, Scordamaglia A, *et al.* On the functional consequences of bronchial basement membrane thickening. *J Appl Physiol* 2001;**91**:1035-1040.
- 32 **Zihlif N**, Paraskakis E, Lex C, *et al.* Correlation between cough frequency and airway inflammation in children with primary ciliary dyskinesia. *Pediatr Pulmonol* 2005;**39**:551-557.
- 33 **Taube C**, Duez C, Cui ZH, *et al.* The Role of IL-13 in Established Allergic Airway Disease. *J Immunol* 2002;**169**:6482-6489.
- 34 **Noah TL**, Black HR, Cheng PW, *et al.* Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. *Journal of Infectious Diseases* 1997;**175**:638-647.
- 35 **Bonfield TL**, Panuska JR, Konstan MW, *et al.* Inflammatory cytokines in cystic fibrosis lungs. *Am J Respir Crit Care Med* 1995;**152**:2111-2118.

Figure legends

Figure 1 The molar ratio of MMP-9:TIMP-1 in BALF correlated with FEV₁ in the CF group ($r=-0.47$, $p<0.05$). Closed circles represent those cases with a pulmonary exacerbation, open circles represent stable cases.

Figure 2 Glycosaminoglycan concentration in BALF in each patient group. Median glycosaminoglycan concentration was significantly greater in the CF group compared to the CRS and control groups; $***p<0.001$.

Figure 3 Glycosaminoglycan concentration in BALF correlated with log₁₀ neutrophil concentration in the CF group ($r=0.85$, $p<0.001$). Closed circles represent those cases with a pulmonary exacerbation, open circles represent stable cases.

Figure 4 Elastin concentration in BALF correlated with FEV₁ (% predicted) in the CF group ($r=0.45$, $p<0.05$). Closed circles represent those cases with a pulmonary exacerbation, open circles represent stable cases.

Figure 5 Reticular basement membrane (RBM) thickness in each patient group. Median RBM thickness was significantly greater in the CF group compared to controls; $**p<0.01$. Number of successful biopsies in each group were 24 (CF), 6 (PCD), CRS (16), Controls (6).

Figure 6 RBM thickness correlated with total TGF- β_1 concentration in BALF in the CF group ($r=0.53$, $p=0.01$). Closed circles represent those cases with a pulmonary exacerbation, open circles represent stable cases.









